The highest approved dose of tirzepatide is 15 mg, injected once weekly. This applies to both brand names: Mounjaro (for type 2 diabetes) and Zepbound (for weight management). You don’t start at 15 mg, though. It takes a minimum of 20 weeks to reach the maximum dose through a gradual step-up process designed to reduce side effects.
How the Dose Escalation Works
Tirzepatide starts at 2.5 mg once weekly for the first four weeks. That starting dose isn’t a maintenance dose; it exists solely to let your body adjust. After four weeks, the dose increases to 5 mg, which is the first true maintenance level.
From there, increases happen in 2.5 mg steps, with at least four weeks between each bump. The full ladder looks like this:
- Weeks 1–4: 2.5 mg
- Weeks 5–8: 5 mg
- Weeks 9–12: 7.5 mg
- Weeks 13–16: 10 mg
- Weeks 17–20: 12.5 mg
- Week 21 onward: 15 mg
Not everyone needs to reach 15 mg. The approved maintenance doses are 5 mg, 10 mg, or 15 mg weekly, and many people get adequate results at a lower level. Your prescriber will base the decision on how well a given dose is controlling blood sugar or supporting weight loss, balanced against how well you tolerate the side effects.
What the 15 mg Dose Achieves
The maximum dose consistently produced the strongest results in clinical trials. In the SURMOUNT-1 trial, which studied tirzepatide for weight loss in people with obesity, participants on 15 mg lost an average of about 22.5% of their starting body weight, roughly 52 pounds. Lower doses still produced significant weight loss (around 16% on average), but the 15 mg group saw the largest reductions.
For blood sugar control, the picture is similar. In the SURPASS-2 trial comparing tirzepatide to semaglutide (Ozempic’s active ingredient) in people with type 2 diabetes, the 15 mg dose lowered A1C by about 2.3 to 2.5 percentage points from baseline. That outperformed both the lower tirzepatide doses and semaglutide at its standard dose. For context, an A1C drop of that size could take someone from poorly controlled diabetes into a near-normal range.
Side Effects Are More Common at Higher Doses
Gastrointestinal problems are the most frequent side effects across all doses, and they tend to increase as the dose goes up. In clinical trials, up to 22% of people taking tirzepatide experienced nausea, and about 1 in 10 reported vomiting. Diarrhea affected 12% to 17% of participants, while constipation showed up in roughly 1 in 13. These symptoms are typically worst during the first few weeks after each dose increase and often improve as your body adjusts.
Less common side effects include heartburn or acid reflux (about 1 in 50 people), injection site reactions (about 1 in 30), and acute gallbladder disease (about 1 in 200). Pancreatitis has been reported but remains rare, at roughly 23 cases per 1,000 new users per year. People taking tirzepatide alongside insulin face a small risk of dangerously low blood sugar, reported in 1% to 2% of trial participants in that combination.
The gradual dose escalation schedule exists specifically to manage these side effects. Jumping straight to 15 mg would likely cause severe nausea and vomiting in most people. The four-week intervals give your gut time to adapt before the next increase.
Available Pen Strengths
Each tirzepatide pen is a single-dose, prefilled device. The pens come in six strengths matching every step of the escalation: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Each delivers 0.5 mL of solution. You inject once weekly at any time of day, with or without food, and the injection site can be the abdomen, thigh, or upper arm.
There is no option to combine two lower-dose pens to exceed 15 mg. The 15 mg pen is the highest strength manufactured, and 15 mg once weekly is the ceiling of the approved dosing range.
Could Higher Doses Come in the Future?
Eli Lilly, the maker of tirzepatide, is running a Phase 2 trial testing doses above 15 mg in people with type 2 diabetes and obesity. The trial includes two experimental “high dose” arms alongside the current standard dose and a placebo. The specific milligram targets for those higher arms haven’t been publicly disclosed. Phase 2 trials are designed to evaluate safety and find the right dose, so it will be years before any higher dose could reach the market, if the results support it.